Crispr Therapeutics is a biotechnology business based in the US. Crispr Therapeutics shares (CRSP) are listed on the NASDAQ and all prices are listed in US Dollars. Crispr Therapeutics employs 407 staff and has a trailing 12-month revenue of around $271.7 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $57.57 |
|---|---|
| 52-week range | $37.55 - $91.10 |
| 50-day moving average | $57.13 |
| 200-day moving average | $61.37 |
| Wall St. target price | $84.29 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-2.70 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $57.57 from 2024-07-25
| 1 week (2024-07-19) | 5.52% |
|---|---|
| 1 month (2024-06-26) | 1.66% |
| 3 months (2024-04-26) | 6.79% |
| 6 months (2024-01-26) | -5.64% |
| 1 year (2023-07-26) | 0.51% |
|---|---|
| 2 years (2022-07-26) | -25.35% |
| 3 years (2021-07-26) | 119.22 |
| 5 years (2019-07-26) | 10.88% |
| Revenue TTM | $271.7 million |
|---|---|
| Gross profit TTM | $-570,697,000 |
| Return on assets TTM | -7.97% |
| Return on equity TTM | -11.02% |
| Profit margin | -79.92% |
| Book value | $24.56 |
| Market Capitalization | $4.9 billion |
TTM: trailing 12 months
We're not expecting Crispr Therapeutics to pay a dividend over the next 12 months.
Crispr Therapeutics's shares were split on a 333333:100 basis on 18 July 2016. So if you had owned 100 shares the day before before the split, the next day you'd have owned 333333 shares. This wouldn't directly have changed the overall worth of your Crispr Therapeutics shares – just the quantity. However, indirectly, the new 100% lower share price could have impacted the market appetite for Crispr Therapeutics shares which in turn could have impacted Crispr Therapeutics's share price.
Over the last 12 months, Crispr Therapeutics's shares have ranged in value from as little as $37.55 up to $91.1. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Crispr Therapeutics's is 1.695. This would suggest that Crispr Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease, and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmunune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and VCTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, ViaCyte, Inc. , Nkarta, Inc.
Steps to owning and managing ZTEK, with 24-hour and historical pricing before you buy.
Steps to owning and managing MYNZ, with 24-hour and historical pricing before you buy.
Steps to owning and managing ATAI, with 24-hour and historical pricing before you buy.
Steps to owning and managing OWLT, with 24-hour and historical pricing before you buy.
Steps to owning and managing LLY, with 24-hour and historical pricing before you buy.
Steps to owning and managing HUM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ILMN, with 24-hour and historical pricing before you buy.
Steps to owning and managing UNH, with 24-hour and historical pricing before you buy.
Steps to owning and managing PFE, with 24-hour and historical pricing before you buy.
Steps to owning and managing JNJ, with 24-hour and historical pricing before you buy.